Proangiogenic tumor proteins as potential predictive or prognostic biomarkers for bevacizumab therapy in metastatic colorectal cancer

Maressa A. Bruhn, Amanda R. Townsend, Chee Khoon Lee, Aravind Shivasami, Timothy J. Price, Joe Wrin, Georgia Arentz, Niall C. Tebbutt, Christopher Hocking, David Cunningham, Jennifer E. Hardingham

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Tumor biomarkers to more accurately predict a patient's response to a given therapy are much needed in oncology practice. For metastatic colorectal cancer the anti-vascular endothelial growth factor (VEGF) monoclonal antibody bevacizumab is now commonly included in first-line therapy regimens and has led to modest but significant improvements in patient outcomes compared with chemotherapy. Given the modest gains there is a pressing need for predictive biomarkers to better identify patients who would benefit from this targeted therapy. We used a multiplex protein assay to determine the tumor expression levels of the proangiogenic proteins IL-6, IL-8, bFGF, PDGF-BB and VEGF-A in formalin-fixed paraffin-embedded tumors from the MAX clinical trial patients with available tissue samples. Patients were dichotomized into "low" vs. "high" expression subgroups based on median baseline levels to correlate with objective response rate (ORR), progression-free survival (PFS) and overall survival (OS). "Low" tumor VEGF-A level was predictive of better ORR for bevacizumab [ORR (low) 53% vs. (high) 19%, interaction p = 0.03] but not for PFS [hazard ratio, HR (low) 0.73 vs. (high) 0.62, interaction p = 0.68] in the comparison of capecitabine (C) versus C and bevacizumab (CB) and CB plus mitomycin (M). When analyzed as a dichotomized variable, "high" VEGF-A was prognostic for shorter PFS (unadjusted HR 1.34, p = 0.06; adjusted HR 1.55, p = 0.008). The other four proteins were neither predictive of bevacizumab benefits nor prognostic for ORR, PFS or OS. "Low" tumor VEGF-A was associated with longer PFS after adjustment for other baseline factors. Proangiogenic proteins were not predictive of benefit with bevacizumab for PFS. What's new? There is a pressing need for predictive biomarkers to better identify metastatic colorectal cancer patients who would benefit from anti-VEGF monoclonal antibody bevacizumab therapy. This study is the first to measure the expression levels of a panel of angiogenic proteins from FFPE tumors and to also use a multiplex assay platform-an advantage given the limited amount of tissue available from clinical trials. Low tumor VEGF-A was associated with significantly longer progression free survival after adjustment for other baseline factors. However neither VEGF-A, nor the other angiogenic proteins IL-6, IL-8, bFGF or PDGF-BB, were predictive of outcome for bevacizumab therapy.

LanguageEnglish
Pages731-741
Number of pages11
JournalInternational Journal of Cancer
Volume135
Issue number3
DOIs
Publication statusPublished - 1 Aug 2014
Externally publishedYes

Keywords

  • Angiogenic proteins
  • Bevacizumab therapy
  • Predictive biomarkers

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Bruhn, M. A., Townsend, A. R., Khoon Lee, C., Shivasami, A., Price, T. J., Wrin, J., ... Hardingham, J. E. (2014). Proangiogenic tumor proteins as potential predictive or prognostic biomarkers for bevacizumab therapy in metastatic colorectal cancer. International Journal of Cancer, 135(3), 731-741. https://doi.org/10.1002/ijc.28698
Bruhn, Maressa A. ; Townsend, Amanda R. ; Khoon Lee, Chee ; Shivasami, Aravind ; Price, Timothy J. ; Wrin, Joe ; Arentz, Georgia ; Tebbutt, Niall C. ; Hocking, Christopher ; Cunningham, David ; Hardingham, Jennifer E. / Proangiogenic tumor proteins as potential predictive or prognostic biomarkers for bevacizumab therapy in metastatic colorectal cancer. In: International Journal of Cancer. 2014 ; Vol. 135, No. 3. pp. 731-741.
@article{406cc47167754eceba8fe549a69913ba,
title = "Proangiogenic tumor proteins as potential predictive or prognostic biomarkers for bevacizumab therapy in metastatic colorectal cancer",
abstract = "Tumor biomarkers to more accurately predict a patient's response to a given therapy are much needed in oncology practice. For metastatic colorectal cancer the anti-vascular endothelial growth factor (VEGF) monoclonal antibody bevacizumab is now commonly included in first-line therapy regimens and has led to modest but significant improvements in patient outcomes compared with chemotherapy. Given the modest gains there is a pressing need for predictive biomarkers to better identify patients who would benefit from this targeted therapy. We used a multiplex protein assay to determine the tumor expression levels of the proangiogenic proteins IL-6, IL-8, bFGF, PDGF-BB and VEGF-A in formalin-fixed paraffin-embedded tumors from the MAX clinical trial patients with available tissue samples. Patients were dichotomized into {"}low{"} vs. {"}high{"} expression subgroups based on median baseline levels to correlate with objective response rate (ORR), progression-free survival (PFS) and overall survival (OS). {"}Low{"} tumor VEGF-A level was predictive of better ORR for bevacizumab [ORR (low) 53{\%} vs. (high) 19{\%}, interaction p = 0.03] but not for PFS [hazard ratio, HR (low) 0.73 vs. (high) 0.62, interaction p = 0.68] in the comparison of capecitabine (C) versus C and bevacizumab (CB) and CB plus mitomycin (M). When analyzed as a dichotomized variable, {"}high{"} VEGF-A was prognostic for shorter PFS (unadjusted HR 1.34, p = 0.06; adjusted HR 1.55, p = 0.008). The other four proteins were neither predictive of bevacizumab benefits nor prognostic for ORR, PFS or OS. {"}Low{"} tumor VEGF-A was associated with longer PFS after adjustment for other baseline factors. Proangiogenic proteins were not predictive of benefit with bevacizumab for PFS. What's new? There is a pressing need for predictive biomarkers to better identify metastatic colorectal cancer patients who would benefit from anti-VEGF monoclonal antibody bevacizumab therapy. This study is the first to measure the expression levels of a panel of angiogenic proteins from FFPE tumors and to also use a multiplex assay platform-an advantage given the limited amount of tissue available from clinical trials. Low tumor VEGF-A was associated with significantly longer progression free survival after adjustment for other baseline factors. However neither VEGF-A, nor the other angiogenic proteins IL-6, IL-8, bFGF or PDGF-BB, were predictive of outcome for bevacizumab therapy.",
keywords = "Angiogenic proteins, Bevacizumab therapy, Predictive biomarkers",
author = "Bruhn, {Maressa A.} and Townsend, {Amanda R.} and {Khoon Lee}, Chee and Aravind Shivasami and Price, {Timothy J.} and Joe Wrin and Georgia Arentz and Tebbutt, {Niall C.} and Christopher Hocking and David Cunningham and Hardingham, {Jennifer E.}",
year = "2014",
month = "8",
day = "1",
doi = "10.1002/ijc.28698",
language = "English",
volume = "135",
pages = "731--741",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "3",

}

Bruhn, MA, Townsend, AR, Khoon Lee, C, Shivasami, A, Price, TJ, Wrin, J, Arentz, G, Tebbutt, NC, Hocking, C, Cunningham, D & Hardingham, JE 2014, 'Proangiogenic tumor proteins as potential predictive or prognostic biomarkers for bevacizumab therapy in metastatic colorectal cancer', International Journal of Cancer, vol. 135, no. 3, pp. 731-741. https://doi.org/10.1002/ijc.28698

Proangiogenic tumor proteins as potential predictive or prognostic biomarkers for bevacizumab therapy in metastatic colorectal cancer. / Bruhn, Maressa A.; Townsend, Amanda R.; Khoon Lee, Chee; Shivasami, Aravind; Price, Timothy J.; Wrin, Joe; Arentz, Georgia; Tebbutt, Niall C.; Hocking, Christopher; Cunningham, David; Hardingham, Jennifer E.

In: International Journal of Cancer, Vol. 135, No. 3, 01.08.2014, p. 731-741.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Proangiogenic tumor proteins as potential predictive or prognostic biomarkers for bevacizumab therapy in metastatic colorectal cancer

AU - Bruhn, Maressa A.

AU - Townsend, Amanda R.

AU - Khoon Lee, Chee

AU - Shivasami, Aravind

AU - Price, Timothy J.

AU - Wrin, Joe

AU - Arentz, Georgia

AU - Tebbutt, Niall C.

AU - Hocking, Christopher

AU - Cunningham, David

AU - Hardingham, Jennifer E.

PY - 2014/8/1

Y1 - 2014/8/1

N2 - Tumor biomarkers to more accurately predict a patient's response to a given therapy are much needed in oncology practice. For metastatic colorectal cancer the anti-vascular endothelial growth factor (VEGF) monoclonal antibody bevacizumab is now commonly included in first-line therapy regimens and has led to modest but significant improvements in patient outcomes compared with chemotherapy. Given the modest gains there is a pressing need for predictive biomarkers to better identify patients who would benefit from this targeted therapy. We used a multiplex protein assay to determine the tumor expression levels of the proangiogenic proteins IL-6, IL-8, bFGF, PDGF-BB and VEGF-A in formalin-fixed paraffin-embedded tumors from the MAX clinical trial patients with available tissue samples. Patients were dichotomized into "low" vs. "high" expression subgroups based on median baseline levels to correlate with objective response rate (ORR), progression-free survival (PFS) and overall survival (OS). "Low" tumor VEGF-A level was predictive of better ORR for bevacizumab [ORR (low) 53% vs. (high) 19%, interaction p = 0.03] but not for PFS [hazard ratio, HR (low) 0.73 vs. (high) 0.62, interaction p = 0.68] in the comparison of capecitabine (C) versus C and bevacizumab (CB) and CB plus mitomycin (M). When analyzed as a dichotomized variable, "high" VEGF-A was prognostic for shorter PFS (unadjusted HR 1.34, p = 0.06; adjusted HR 1.55, p = 0.008). The other four proteins were neither predictive of bevacizumab benefits nor prognostic for ORR, PFS or OS. "Low" tumor VEGF-A was associated with longer PFS after adjustment for other baseline factors. Proangiogenic proteins were not predictive of benefit with bevacizumab for PFS. What's new? There is a pressing need for predictive biomarkers to better identify metastatic colorectal cancer patients who would benefit from anti-VEGF monoclonal antibody bevacizumab therapy. This study is the first to measure the expression levels of a panel of angiogenic proteins from FFPE tumors and to also use a multiplex assay platform-an advantage given the limited amount of tissue available from clinical trials. Low tumor VEGF-A was associated with significantly longer progression free survival after adjustment for other baseline factors. However neither VEGF-A, nor the other angiogenic proteins IL-6, IL-8, bFGF or PDGF-BB, were predictive of outcome for bevacizumab therapy.

AB - Tumor biomarkers to more accurately predict a patient's response to a given therapy are much needed in oncology practice. For metastatic colorectal cancer the anti-vascular endothelial growth factor (VEGF) monoclonal antibody bevacizumab is now commonly included in first-line therapy regimens and has led to modest but significant improvements in patient outcomes compared with chemotherapy. Given the modest gains there is a pressing need for predictive biomarkers to better identify patients who would benefit from this targeted therapy. We used a multiplex protein assay to determine the tumor expression levels of the proangiogenic proteins IL-6, IL-8, bFGF, PDGF-BB and VEGF-A in formalin-fixed paraffin-embedded tumors from the MAX clinical trial patients with available tissue samples. Patients were dichotomized into "low" vs. "high" expression subgroups based on median baseline levels to correlate with objective response rate (ORR), progression-free survival (PFS) and overall survival (OS). "Low" tumor VEGF-A level was predictive of better ORR for bevacizumab [ORR (low) 53% vs. (high) 19%, interaction p = 0.03] but not for PFS [hazard ratio, HR (low) 0.73 vs. (high) 0.62, interaction p = 0.68] in the comparison of capecitabine (C) versus C and bevacizumab (CB) and CB plus mitomycin (M). When analyzed as a dichotomized variable, "high" VEGF-A was prognostic for shorter PFS (unadjusted HR 1.34, p = 0.06; adjusted HR 1.55, p = 0.008). The other four proteins were neither predictive of bevacizumab benefits nor prognostic for ORR, PFS or OS. "Low" tumor VEGF-A was associated with longer PFS after adjustment for other baseline factors. Proangiogenic proteins were not predictive of benefit with bevacizumab for PFS. What's new? There is a pressing need for predictive biomarkers to better identify metastatic colorectal cancer patients who would benefit from anti-VEGF monoclonal antibody bevacizumab therapy. This study is the first to measure the expression levels of a panel of angiogenic proteins from FFPE tumors and to also use a multiplex assay platform-an advantage given the limited amount of tissue available from clinical trials. Low tumor VEGF-A was associated with significantly longer progression free survival after adjustment for other baseline factors. However neither VEGF-A, nor the other angiogenic proteins IL-6, IL-8, bFGF or PDGF-BB, were predictive of outcome for bevacizumab therapy.

KW - Angiogenic proteins

KW - Bevacizumab therapy

KW - Predictive biomarkers

UR - http://www.scopus.com/inward/record.url?scp=84901057832&partnerID=8YFLogxK

U2 - 10.1002/ijc.28698

DO - 10.1002/ijc.28698

M3 - Article

VL - 135

SP - 731

EP - 741

JO - International Journal of Cancer

T2 - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 3

ER -